Trial Profile
Evaluation of the efficacy and safety of trimonthly intravitreal injection of aflibercept for retinal vein occlusion
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Jul 2022
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Retinal vein occlusion
- Focus Therapeutic Use
- 05 Jul 2022 Status changed from recruiting to active, no longer recruiting.
- 24 May 2016 New trial record